Article
Dermatology
Alessandra Narcisi, Mario Valenti, Andrea Cortese, Francesco Toso, Giulia Pavia, Luigi Gargiulo, Riccardo Borroni, Antonio Costanzo
Summary: The study retrospectively compared the efficacy of anti-interleukin (IL) 23 drugs and anti-IL17 or anti-IL17RA biologics in treating scalp psoriasis, showing both types of drugs to be effective with anti-IL17 drugs achieving a faster reduction in lesions while anti-IL23 monoclonal antibodies were slightly superior in maintaining clinical improvement.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Jose Carlos Armario-Hita, Amalia Perez-Gil, Fiorella Vasquez Chinchay, Manuel Galan-Gutierrez
Summary: The IL23/Th17 axis plays a strategic role in psoriasis, and Guselkumab, a selective inhibitor of the IL23p19 subunit, has shown increased efficacy, safety, and survival in the treatment of psoriasis. This study evaluated the effectiveness, safety, and survival of Guselkumab in real clinical practice after anti-TNF alpha, anti-IL17, and/or anti-IL12/23 treatments. The results showed that Guselkumab was effective and safe, with high survival rates, even after previous biological therapy.
DERMATOLOGIC THERAPY
(2022)
Review
Immunology
Heike Schmitt, Markus F. Neurath, Raja Atreya
Summary: Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract influenced by genetic susceptibility, environmental factors, and intestinal microbiome. Pro-inflammatory cytokines IL17 and IL23 play crucial roles in the pathogenesis of CD by causing excessive activation of the mucosal immune system. Treatments targeting these cytokines, such as selective IL23 inhibitors, have shown promising results in CD patients who failed previous anti-TNF therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biology
Hanieh Kolahdooz, Vahid Khori, Vahid Erfani-Moghadam, Fatemeh Livani, Saeed Mohammadi, Ali Memarian
Summary: Psoriasis is characterized by epidermal hyperplasia and infiltration of immune cells. Poor permeation of curcumin through the skin is a major cause of medication failures. Curcumin-niosome formulations showed significant improvement in the skin lesions of psoriasis patients, with reduction in redness and scaling. Gene expression analysis indicated downregulation of IL17/IL23 immunopathogenic axis in the CUR-NIO treated group.
Article
Rheumatology
Mariagrazia Lorenzin, Augusta Ortolan, Giacomo Cozzi, Antonia Calligaro, Maria Favaro, Teresa Del Ross, Andrea Doria, Roberta Ramonda
Summary: This study evaluated potential predictors of first bDMARD failure and factors associated with failure of multiple therapies in PsA patients. It found that female patients were more likely to discontinue treatment with first bDMARD, while initiating therapy before 2015 was protective.
CLINICAL RHEUMATOLOGY
(2021)
Article
Dermatology
Matteo Megna, Luca Potestio, Angelo Ruggiero, Elisa Camela, Gabriella Fabbrocini
Summary: This real-life study evaluated the long-term efficacy and safety of guselkumab in patients who previously failed anti-IL17 treatments. The results showed significant improvement in Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) at each follow-up, as well as improvement in Nail Psoriasis Severity Index (NAPSI) after 28 weeks. Only a small percentage of patients discontinued guselkumab due to secondary inefficacy.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2022)
Review
Immunology
Matteo Vecellio, Vivien Xanath Hake, Connor Davidson, Maria Cristina Carena, B. Paul Wordsworth, Carlo Selmi
Summary: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis, with genetic predisposition playing a key role in its development. The IL-23/IL-17 axis is highlighted as important in the immunopathogenesis of PsA.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Jie Zhang, Si-Hang Wang, Ya-Gang Zuo
Summary: This study aimed to investigate the clinical features of biologics-induced bullous pemphigoid (BP) and the therapeutic effects of those agents for BP, exploring the underlying pathophysiological mechanisms. The study found that biologics can both induce and treat BP, which might be associated with a helper T cells Th1/Th2 imbalance, complicated inflammatory networks, and a specific individual microenvironment. This finding provides a new perspective and alternative therapeutic options for BP.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Rheumatology
Burcu Yagiz, Nihal Lermi, Belkis N. Coskun, Ediz Dalkilic, Sedat Kiraz, Abdulsamet Erden, Ihsan Ertenli, Emine Duran, Emre Bilgin, Recep Yilmaz, Askin Ates, Abdurrahman Tufan, Hamit Kucuk, Ridvan Mercan, Haluk Cinakli, Servet Akar, Nazife S. Yasar Bilge, Timucin Kasifoglu, Suemeyye M. Turk, Emel Orge Gonullu, Cemal Bes, Nilufer Alpay Kanitez, Hakan Emmungil, Umut Kalyoncu, Yavuz Pehlivan
Summary: This study aims to assess the clinical characteristics, predictive factors, and practical algorithms of paradoxical reactions, specifically paradoxical psoriasis. The results show that switching to another TNFi medication is effective in treating patients with paradoxical psoriasis. Pustular and palmoplantar psoriasis are the most common types of paradoxical reactions.
Review
Immunology
Helene Bugaut, Selim Aractingi
Summary: Psoriasis is a common chronic skin inflammatory disease associated with other conditions like Crohn's disease and metabolic syndrome. IL17 and IL23 play crucial roles in psoriasis, with current treatments focusing on targeting them with monoclonal antibodies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Xiaomin Yao, Zhen Zhu, Upasana Manandhar, Han Liao, Tiexi Yu, Yueying Wang, Yawen Bian, Bo Zhang, Xuanhong Zhang, Jun Xie, Jiquan Song
Summary: This study identified the role of GNL3 in the pathogenesis of psoriasis vulgaris. GNL3 was found to regulate the IL23/IL17 axis, highlighting its potential as a target for effective treatment in the future.
Letter
Dermatology
Antonio Carriero, Ennio Lubrano, Valentina Picerno, Angela Anna Padula, Salvatore D'Angelo
Summary: Paradoxical psoriatic arthritis (PPsA) may be linked to guselkumab treatment, possibly due to cytokine imbalance.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Angelo Ruggiero, Fabrizio Martora, Vincenzo Picone, Laura Marano, Gabriella Fabbrocini, Claudio Marasca
Summary: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with unclear pathogenesis. Recent research has improved our understanding of the mechanisms behind HS lesions, including follicular occlusion and rupture, immune response activation, and imbalanced cytokine production. Paradoxical HS occurrences have been increasingly reported during treatment with biologic drugs.
Article
Dermatology
Claudio Bonifati, Aldo Morrone, Antonio Cristaudo, Dario Graceffa
Summary: New biologic drugs targeting interleukin-17 have shown quick effectiveness in treating psoriasis, but there is limited real-life data on switching to biologics targeting interleukin-23 in patients who have failed previous treatments.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Qianqian Zhou, Shengru Zhou, Huizi Xiong, Jianqiu Yang, Ziliang Yang, Naihui Zhou, Jinzhu Mao, Min Li
Summary: Psoriasis is an immune-mediated chronic inflammatory skin disease. While biologic agents have become increasingly important in its treatment, they can also cause paradoxical reactions as a new type of side effect.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Letter
Dermatology
Fabrizio Martora, Alessia Villani, Claudio Marasca, Gabriella Fabbrocini, Luca Potestio
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Dermatology
Matteo Megna, Teresa Battista, Luca Potestio, Angelo Ruggiero, Virginia Ventura, Gabriella Fabbrocini, Vincenzo Picone
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Letter
Dermatology
Luca Potestio, Alessia Villani, Flavia Raia, Gabriella Fabbrocini, Fabrizio Martora
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Letter
Dermatology
Luca Potestio, Gabriella Fabbrocini, Michela D'Agostino, Ilaria Piscitelli, Fabrizio Martora
JOURNAL OF COSMETIC DERMATOLOGY
(2023)
Article
Pharmacology & Pharmacy
Alessia Villani, Massimiliano Scalvenzi, Giuseppe Micali, Francesco Lacarrubba, Lucia Genco, Angelo Ruggiero, Luigi Fornaro, Gianluca Guerrasio, Luca Potestio
Summary: Surgery is the standard treatment for most basal cell carcinomas (BCC), but in some cases, radiotherapy, ablative and topical treatments may also be valuable options. Locally advanced BCCs (laBCC) and metastatic BCC, also referred to as 'difficult-to-treat' BCC, pose a challenge for current treatment approaches. The development of new selective therapies targeting the Hedgehog (HH) pathway, such as sonidegib, has shown promising results in managing difficult-to-treat BCC.
EXPERT OPINION ON DRUG SAFETY
(2023)
Article
Pharmacology & Pharmacy
Angelo Ruggiero, Luca Potestio, Fabrizio Martora, Alessia Villani, Rosita Comune, Matteo Megna
Summary: Biological treatments have revolutionized the management of moderate-to-severe psoriasis, and bimekizumab, a novel IL-17 inhibitor, shows unique efficacy and safety profiles compared to other biologics. This review evaluates the safety of bimekizumab in treating moderate-to-severe plaque psoriasis and highlights its superior efficacy compared to other biological classes.
EXPERT OPINION ON DRUG SAFETY
(2023)
Review
Pharmacology & Pharmacy
Alessandro Villa, Stephen T. T. Sonis
Summary: Oral mucositis (OM) is a common and damaging side effect of head and neck radiation therapy that may affect patients' adherence to treatment. There has been increasing interest in the development of effective interventions for OM due to the unmet clinical need, recent clinical trial successes, and commercial potential. This review focuses on drugs that have recently been assessed in clinical trials and those that are still under clinical study for the prevention or treatment of radiation-associated OM.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Review
Pharmacology & Pharmacy
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Sabatino Pallotta, Matteo Megna
Summary: Psoriasis is a burdensome syndrome that greatly affects patients' quality of life with skin and non-skin manifestations. The presence of comorbidities often limits the most appropriate treatment, but the development of drugs effective for diseases with common pathogenetic pathways will overcome this limitation.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Review
Biochemistry & Molecular Biology
Luca Potestio, Teresa Battista, Sara Cacciapuoti, Angelo Ruggiero, Fabrizio Martora, Luigi Fornaro, Elisa Camela, Matteo Megna
Summary: COVID-19 vaccination is crucial in overcoming the pandemic, but it may cause mild to moderate adverse events, including cutaneous reactions such as psoriasis exacerbation or new-onset psoriasis. This manuscript aims to review the literature and explore the possible pathogenetic mechanisms of post-vaccination psoriasis exacerbations and new-onset psoriasis.
Review
Dermatology
Matteo Megna, Elisa Camela, Angelo Ruggiero, Teresa Battista, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Summary: Generalized pustular psoriasis (GPP) is a severe form of psoriasis characterized by recurring episodes of widespread erythema with pustules. The pathology of GPP involves irregular innate and adaptive immune responses, with the IL36 pathway being implicated. Conventional systemic drugs used for plaque psoriasis are commonly employed as the first-line treatment for GPP, but biologic drugs show promise as an alternative option. The recent approval of spesolimab, an anti-IL36 receptor monoclonal antibody, for GPP highlights the potential of biologic therapies in GPP treatment.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Review
Dermatology
Luca Potestio, Fabrizio Martora, Gabriella Fabbrocini, Teresa Battista, Matteo Megna
Summary: The introduction of biologic drugs revolutionized the treatment of psoriasis, but the safety and effectiveness of COVID-19 vaccination in psoriasis patients undergoing biologic treatment are still uncertain.
PSORIASIS-TARGETS AND THERAPY
(2023)
Review
Dermatology
Luca Potestio, Matteo Megna, Alessia Villani, Sara Cacciapuoti, Massimiliano Scalvenzi, Fabrizio Martora
Summary: COVID-19 has caused a global health crisis and revolutionized every aspect of human life. Vaccines have been the most important measure to reduce the transmission and severity of the virus. The vaccination campaign has been successful, but monitoring and addressing vaccine-related adverse events are crucial. Various cutaneous reactions, including viral reactivations, have been reported, emphasizing the importance of early diagnosis and accurate treatment.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)